Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma.

MLA

Breitenecker, Kristina, et al. “Synergism of the Receptor Tyrosine Kinase Axl with ErbB Receptors Mediates Resistance to Regorafenib in Hepatocellular Carcinoma.” Frontiers in Oncology, vol. 13, Sept. 2023, p. 1238883. EBSCOhost, https://doi.org/10.3389/fonc.2023.1238883.

APA

Breitenecker, K., Hedrich, V., Pupp, F., Chen, D., Řezníčková, E., Ortmayr, G., Huber, H., Weber, G., Balcar, L., Pinter, M., & Mikulits, W. (2023). Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. Frontiers in Oncology, 13, 1238883. https://doi.org/10.3389/fonc.2023.1238883

Chicago

Breitenecker, Kristina, Viola Hedrich, Franziska Pupp, Doris Chen, Eva Řezníčková, Gregor Ortmayr, Heidemarie Huber, et al. 2023. “Synergism of the Receptor Tyrosine Kinase Axl with ErbB Receptors Mediates Resistance to Regorafenib in Hepatocellular Carcinoma.” Frontiers in Oncology 13 (September): 1238883. doi:10.3389/fonc.2023.1238883.